Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Trial of ABI-010 & ABI-007 in Patients With Advanced Non-Hematologic Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00820768
Recruitment Status : Withdrawn
First Posted : January 12, 2009
Last Update Posted : April 11, 2018
Sponsor:
Information provided by (Responsible Party):
Celgene

Brief Summary:
To determine MTD and DLT of ABI-010 given weekly every three weeks followed by one week of rest (Cycle 1). Determine MLD and DLT in combination with ABI-007; to characterize the toxicities of ABI-010 alone and in combination with ABI-007.

Condition or disease Intervention/treatment Phase
Solid Tumor Drug: ABI-010 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I of ABI-010 (Nab-17-AAG) and ABI-007 (Abraxane) Administered Weekly in Patients With Advanced Non-Hematologic Malignancies
Actual Study Start Date : April 1, 2012
Estimated Primary Completion Date : April 1, 2013
Estimated Study Completion Date : April 1, 2014

Resource links provided by the National Library of Medicine

Drug Information available for: Paclitaxel

Arm Intervention/treatment
Experimental: ABI-010 Drug: ABI-010
17-AAG and ABI-007
Other Name: 17-AAG and ABI-007




Primary Outcome Measures :
  1. The primary objectives of this study are to determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of ABI-010 given weekly for 3 weeks followed by 1 week of rest (Cycle 1); to determine MTD and DLTs of ABI-010 given in combination [ Time Frame: EOS and Follow-Up ]

Secondary Outcome Measures :
  1. To determine the pharmacokinetic parameters for ABI-010 when given on a weekly schedule alone and in combination with ABI-007; determine preliminary efficacy of ABI-010 when given on a weekly schedule in combination with ABI-007 [ Time Frame: EOS and Follow-Up ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria: Each subject must meet the following criteria to be enrolled in this study:

  1. Pathologically confirmed advanced solid tumor malignancy.
  2. Measurable or evaluable advanced solid tumors.
  3. Patients with advanced solid tumor malignancy who failed standard therapy or for whom no standard therapy exists. Patients failing standard therapy should have received no more than 3 prior chemotherapy regimens.
  4. Patients must have recovered for at least 3 weeks from prior treatment regimens and have no residual toxicity > Grade 2 (with the exception of peripheral neuropathy which must have improved to ≤ Grade 1).
  5. Patient should have full recovery from any reversible side effects of prior chemotherapy.
  6. Patient should have full recovery for at least 4 weeks since major surgery.
  7. ECOG performance status 0-2.
  8. Age ≥18 years.
  9. Patient must have the following blood counts at Baseline:

    • WBC ≥ 3.0 x 10 cells/L.
    • ANC ≥ 1.5 x 10 cells/L.
    • Platelets ≥ 100 x 10 cells/L.
    • Hgb ≥ 9grams/dL.
  10. Patient must have the following blood chemistry levels at Baseline:

    • AST (SGOT), ALT (SGPT) ≤ 1.5x upper limit of normal range (ULN);
    • Total Bilirubin ≤ ULN;
    • Alkaline phosphatase ≤ 2.5x ULN (unless bone metastasis is present in the absence of liver metastasis;
    • Creatinine ≤ 1.5 mg/dL
  11. Peripheral neuropathy Grade ≤ 1 by NCI CTCAE V3.0.
  12. Female of childbearing potential with negative serum pregnancy test within 72 hours prior to the first dose of study drug.
  13. Males and females with reproductive potential must agree to utilize contraception considered adequate and appropriate by the investigator (including one barrier method) for the duration of the study and for 2 months after the end of study.
  14. Life expectancy ≥ 3 months.
  15. Informed consent document has been obtained.
  16. If obese, a patient must be treated with doses calculated using his/her actual BSA (the physician must be comfortable treating at the full BSA dose regardless of BSA).

Exclusion Criteria: Subjects who meet any of the following criteria will be excluded from the study.

  1. Concurrent therapy (chemotherapy, hormonal therapy, kinase inhibitors, immunotherapy, etc) for advanced solid tumor.
  2. Patients receiving known CYP450 3A4 inhibitors.
  3. Bisphosphonate therapy is allowed, however, patients should be stable on their current bisphosphonate, with no change, start or stop of treatment within 4 weeks prior to enrollment.
  4. Patients with known brain metastases or leptomeningeal tumor involvement should be excluded from this clinical trial.
  5. Uncontrolled intercurrent illness including, but not limited to, serious ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/ social situations that would limit compliance with study.
  6. Patients with significant cardiovascular disease including congestive heart failure (New York Heart Association Class III or IV), active angina pectoris or recent myocardial infarction (within the last 6 months).
  7. History of other malignancy within the last 5 years which would affect the diagnosis or assessment of advanced solid tumor excluding non-melanomatous skin cancer and cervical carcinoma.
  8. Patients who have received an investigational drug within the previous 3 weeks.
  9. Patient is currently enrolled in any other clinical study in which investigational procedures are performed or investigational therapies are administered. A patient may not enroll in such clinical trials while participating in this study.
  10. Pregnant or nursing women.
  11. Patients with history of allergy or hypersensitivity to the study drug or its excipients.
  12. Patients with marked baseline prolongation of QT/QTc interval (>450 milliseconds).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00820768


Locations
Layout table for location information
United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
Sponsors and Collaborators
Celgene
Investigators
Layout table for investigator information
Principal Investigator: Henry C. Pitot, MD Mayo Clinic
Layout table for additonal information
Responsible Party: Celgene
ClinicalTrials.gov Identifier: NCT00820768    
Other Study ID Numbers: CA501
First Posted: January 12, 2009    Key Record Dates
Last Update Posted: April 11, 2018
Last Verified: April 2018
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms
Albumin-Bound Paclitaxel
Antineoplastic Agents